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Background: Small vessel size remains an independent predictor of restenosis and target
lesion revascularization (TLR) even in the drug-eluting stent (DES) era. It is unknown
whether second-generation DES improve outcomes in this lesion subset. This study aimed
to compare the long-term clinical outcomes between everolimus-eluting stents (EES) and
sirolimus-eluting stents (SES) in small coronary artery diseases.
Methods: A total of 1160 patients treated with EES (n475) or SES (n685) in small
coronary artery lesions (defined as size of the stent implanted of 2.75 mm) were
retrospectively enrolled. Primary end point was ischemia-driven TLR at 12 months.
Secondary end points were major adverse cardiovascular events (MACE; death, myocar-
dial infarction, and target vessel revascularization) and stent thrombosis during 12-month
follow-up.
Results: Baseline characteristics were generally similar between stent groups, with the
exception of a significantly greater prevalence of diabetes mellitus and systemic
hypertension in the EES group. The EES group also had more type C lesions (47.7% vs.
24.5%, p 0.001). At 1 year, there was no significant difference in terms of TLR rate
between EES and SES (5.4% vs. 5.2%, p0.89). During follow-up, MACE occurred in
10.3% of EES- and 12.0% of SES-treated patients (p0.38). Stent thrombosis was lower
in the EES group (0.0% vs. 1.2%, p0.024).
Conclusions: Despite more complex lesions, EES demonstrated comparable clinical
safety and efficacy to SES in small coronary artery interventions. Notably, the EES-treated
patients were associated with a reduction in stent thrombosis.
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Background: Clinicians use data from different sources, such as randomized clinical
trials (RCTs) and registries, to define optimal clinical practice. We assessed the impact of
different study designs on 2-year adverse event rates in 2 studies of Biolimus A9-eluting
stents (BES) – the LEADERS RCT and the e-BioMatrix PMS registry.
Methods: The LEADERS (BES arm 857 pts) and the e-BioMatrix PMS (1102 pts)
enrolled similar patients but had several design differences including patient selection,
degree of monitoring, protocol-driven measurements and event definitions. We expected
lower event rates in the e-BioMatrix PMS consistent with a PP analysis, vs. ITT in
LEADERS. To clarify how the differences in designs affected event rates during different
FU periods, we performed a 2-day landmark analysis to focus on out-of-hospital events.
Results: Baselines were similar between LEADERS and e-BioMatrix PMS e.g. diabetes:
26% vs 24% (p0.32), ACS: 55% vs. 53% (p0.41), STEMI: 16% vs 19% (p0.05)),
although LEADERS had higher prior PCI (36% vs 25% (p0.001)) and prior MI (32%
vs 21% (p0.001)). At 2 years, the e-BioMatrix PMS showed similar rates of cardiac
death (CD) (2.4% vs 3.2%), Q-wave MI (0.8% vs 0.5%) and ci-TVR (6.4% vs 7.7%, p
0.26) vs. LEADERS, but lower rates of all MI (3.1% vs. 6.4%, p0.001). MACE rates
were 9.5% and 13% (p0.01).Although e-BioMatrix showed a lower early definite ST vs
LEADERS (0.5% vs 1.6%, p0.05), the late and very late ST were similar. The 2-day
landmark showed that the lower adverse event rates in the e-BioMatrix PMS compared to
LEADERS were mainly driven by differences in the first 2 days. There were no significant
differences between 3 days and 2 years in MACE, CD, MI, ci-TVR and definite ST.
Conclusions: We found a large degree of reproducibility for event rates2 days. Lower
in-hospital rates in e-BioMatrix PMS are likely due to design differences including PP vs.
ITT analysis, mandatory ECG and biomarker determinations required post-procedure, and
lower biomarker thresholds for MI in LEADERS. This study emphasizes that design
criteria could impact on study results, even when the quality of data collection, monitoring
and FU of a registry is comparable with those of a RCT.
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Background: Drug-eluting stents (DES) are frequently used to treat complex patient and
lesion subsets with good efficacy and safety. This study aimed to compare the in-hospital
and 1-year clinical outcomes of patients with complex clinical and angiographic
characteristics treated with 1st- versus 2nd-generation DES.
Methods: The study included 5190 consecutive patients with 1 of the following
characteristics: Ejection fraction (EF) 30%, chronic renal insufficiency (CRI), cardio-
genic shock, bifurcation, unprotected left main, totally occluded, ACC/AHA Type C
lesion, bypass graft, in-stent restenosis (ISR), presence of thrombus, 1 lesion treated,
and stent implantation length  28 mm. Patients presenting with ST-segment elevation
myocardial infarction (STEMI) were excluded. Clinical outcomes of patients treated with
1st-generation DES (Cypher/Taxus) (n3834) were compared to those treated with
2nd-generation DES (Promux/Xience) (n1356).
Results: Baseline characteristics, non-STEMI (15.3% overall) at presentation, and CRI
(15.1% overall) were similar in both groups. 2nd-generation DES were used more in
insulin-treated diabetics (14.7 vs. 11.7%, p0.005), type C lesions (50.4 vs. 22.7 %,
p0.001), and distal lesions (27.2 vs. 12.8 %, p0.001). 1st-generation DES were
used more in cardiogenic shock (1.7 vs. 0.6%, p0.003), ISR (4.7 vs. 2.8%, p 0.001),
vein graft (6.0 vs. 4.5%, p0.011) and ostial lesions (4.9 vs. 2.4%, p 0.001).
Angiographic success was similar at 99.1% overall. Major in-hospital complications and
1-year cumulative major adverse cardiac events were low overall, but were significantly
higher in the 1st-generation compared to 2nd-generation DES group. (Table).
1st
generation
DES
2nd
generation
DES
P value(n3834) (n1356)
In-hospital
Death 0.9 (33) 0.4 (5) 0.068
Q-wave MI 0.5 (21) 0.1 (2) 0.056
Urgent CABG 0.2 (6) 0.1 (1) 0.684
Stent thrombosis 0.3 (10) 0.1 (1) 0.308
Major in-hospital
complications (death/QWMI/
CABG)
1.4 (52) 0.6 (8) 0.023
1-year
Death 5.6 (214) 3.0 (40) 0.001
Q-wave MI 0.4 (14) 0 (0) 0.028
TLR 5.3 (199) 4.2 (56) 0.117
TVR 7.9 (296) 5.9 (79) 0.019
Cumulative stent thrombosis 1.1 (44) 0.1 (2) 0.001
Cumulative MACE (Death/
QWMI/TVR)
13.0 (499) 8.6 (117) 0.001
Conclusions: In a complex patient population undergoing percutaneous coronary
intervention, DES use results in low in-hospital and 1-year event rates, with better
outcomes observed in 2nd- compared to 1st-generation DES.
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